Sleep Disorders

Introduction to the Scope of Cleveland Clinic's Sleep Disorders Center

Cleveland Clinic’s Sleep Disorders Center, established in 1978, was among the first in the nation dedicated to the diagnosis and treatment of sleep and wake disorders across the entire age spectrum. Accredited by the American Academy of Sleep Medicine, the Sleep Disorders Center provides a comprehensive, multidisciplinary approach to patient care with specialists in Neurology, Pulmonary and Critical Care Medicine, Psychiatry and Psychology, Internal Medicine, Family Medicine, Pediatrics, and Otolaryngology, with a total of 126 caregivers. The program has 52 beds in 7 sleep laboratory locations within the Cleveland Clinic health system.

Reflective of the multifaceted and multidisciplinary strengths of the program, the 2023 Sleep Disorders Center outcomes will include: change in sleep-related symptoms in patients with obstructive sleep apnea (OSA), hypoglossal nerve stimulation patient-reported outcomes, sleep apnea-specific hypoxic and autonomic measures in relation to incident atrial fibrillation, sleep architectural disruption and atrial fibrillation development, survival analysis and sleep-related hypoxia in those with pulmonary hypertension, telemedicine motivational enhancement in those with heart failure and sleep apnea, social determinants of health and sleep study completion rates, patient-reported outcomes of sleep disturbances in Post-Acute Sequelae of COVID-19 infection (PASC), sex-specific differences in inpatient sleep diagnostics, improvement in insomnia-related symptoms following individual cognitive behavioral therapy for insomnia (CBT-I), growth in pediatric care delivery, REM suppressing anti-depressant effects on REM sleep without atonia, a biomarker of REM behavior disorder, psychotropic medication effects on Multiple Sleep Latency Test results, patient reported outcomes on hypersomnia patients of all types, the development of a Hypersomnia Carepath with safety biomarkers of sleepiness, participation in many pharmacotherapy trials, a collaboration with IBM on a Discovery Accelerator award to create a clinical cohort of n=10,000 PSGs to generate time series foundational models for the generation and implementation of new, clinically meaningful metrics beyond the apnea hypopnea index.

​

Overall Sleep Studies

2017 – 2022

Actigraphy/Other = Actigraphy, PAP Nap studies for acclimation, and titration studies with oral pressure therapy, oral appliance, or nasal end expiratory positive pressure, HSAT = home sleep apnea testing, MSLT/MWT = multiple sleep latency test/maintenance of wakefulness test, PAP = positive airway pressure titration study, PSG/EEG = polysomnogram alone or in combination with 18-channel electroencephalography, Split = combination PSG and PAP titration study